Biogen (BIIB) Enterprise Value (2009 - 2026)

Biogen (BIIB) has reported Enterprise Value for 18 consecutive years, with -$4.3 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value fell 64.83% year-over-year to -$4.3 billion; the TTM figure through Mar 2026 stood at -$4.3 billion (down 64.83% YoY), while the FY2025 annual figure was -$3.8 billion, down 60.66% from the prior year.
• Enterprise Value came in at -$4.3 billion for Q1 2026 at Biogen, down from -$3.8 billion in the prior quarter.
• The five-year high for Enterprise Value was -$1.0 billion in Q4 2023, with the low at -$6.1 billion in Q2 2023.
• Average Enterprise Value over 5 years is -$3.4 billion, with a median of -$3.8 billion recorded in 2022.
• Across the five-year window, Enterprise Value soared 78.73% in 2024 and plunged 141.84% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$4.9 billion in 2022, then soared by 78.58% to -$1.0 billion in 2023, then sank by 126.21% to -$2.4 billion in 2024, then slumped by 60.66% to -$3.8 billion in 2025, then slipped by 12.24% to -$4.3 billion in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$4.3 billion, -$3.8 billion, and -$4.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.